ivabradine has been researched along with Atherosclerosis in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, PC; Gaalen, KV; Gijsen, FJH; Meester, EJ; Moerman, AM; Ridwan, RY; Van der Heiden, K; van der Steen, AFW; Xing, R | 1 |
| Chichkanov, GG; Tsorin, IB | 1 |
| Böhm, M; Custodis, F; Laufs, U; Reil, JC | 1 |
| Caetano, J; Delgado Alves, J | 1 |
| Alexopoulos, D; Apostolakis, E; Hahalis, G; Koniari, I; Mavrilas, D; Papadaki, H; Papadimitriou, E; Papalois, A; Poimenidi, E; Xanthopoulou, I | 1 |
| Heusch, G | 1 |
| Thorin, E; Thorin-Trescases, N | 1 |
| Baumhäkel, M; Böhm, M; Custodis, F; Laufs, U; Schlimmer, N | 1 |
| Bach, H; Bernhardt, P; Durst, R; Rottbauer, W; Vasic, D; Walcher, D; Walcher, T | 1 |
| Bahlmann, F; Baumhäkel, M; Böhm, M; Custodis, F; Degen, A; Friedrich, E; Kappl, R; Kohlhaas, M; Laufs, U; Maack, C; Schirmer, SH; Schuh, L | 1 |
| Bolduc, V; Des Rosiers, C; Drouin, A; Duquette, N; Frayne-Robillard, I; Gillis, MA; Tardif, JC; Thorin, E; Thorin-Trescases, N | 1 |
| Daiber, A; Hortmann, M; Kleschyov, AL; Kröller-Schön, S; Münzel, T; Oelze, M; Renné, T; Schulz, E; Torzewski, M; Wenzel, P | 1 |
| Baumhäkel, M; Böhm, M; Custodis, F; Gensch, C; Laufs, U; List, F; Schlimmer, N | 1 |
3 review(s) available for ivabradine and Atherosclerosis
| Article | Year |
|---|---|
[Heart rate reduction due to selective specific inhibition of the If current opens new possibilities in treatment of basic cardiovascular diseases].
Topics: Adrenergic beta-Antagonists; Animals; Atherosclerosis; Benzazepines; Cardiotonic Agents; Heart; Heart Failure; Heart Rate; Humans; Ivabradine; Myocardial Ischemia; Stroke Volume; Ventricular Dysfunction, Left | 2013 |
Heart rate and cardiovascular protection.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atherosclerosis; Benzazepines; Cardiovascular Agents; Clinical Trials as Topic; Heart Failure; Heart Rate; Humans; Hypertension; Ivabradine; Myocardial Ischemia; Risk Factors | 2015 |
Vascular endothelial ageing, heartbeat after heartbeat.
Topics: Adrenergic beta-Antagonists; Aging; Animals; Atherosclerosis; Baroreflex; Benzazepines; Cardiovascular Diseases; Endothelium, Vascular; Heart Rate; Humans; Ivabradine; Nitric Oxide; Pulsatile Flow; Risk Factors; Shear Strength; Stress, Mechanical | 2009 |
10 other study(ies) available for ivabradine and Atherosclerosis
| Article | Year |
|---|---|
The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice.
Topics: Animals; Atherosclerosis; Cardiovascular Agents; Disease Models, Animal; Heart Rate; Hemodynamics; Ivabradine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Stress, Mechanical | 2018 |
Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum.
Topics: Atherosclerosis; Benzazepines; Cardiovascular Diseases; Endothelium, Vascular; Heart Rate; Humans; Ivabradine; Prognosis; Rest; Risk; Risk Factors; Stroke | 2013 |
Inhibition of Atherosclerosis Progression, Intimal Hyperplasia, and Oxidative Stress by Simvastatin and Ivabradine May Reduce Thoracic Aorta's Stiffness in Hypercholesterolemic Rabbits.
Topics: Animals; Antioxidants; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Benzazepines; Diet, Atherogenic; Disease Models, Animal; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperplasia; Ivabradine; Male; Neointima; Oxidative Stress; Plaque, Atherosclerotic; Rabbits; Simvastatin; Vascular Stiffness | 2016 |
Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction.
Topics: Animals; Atherosclerosis; Benzazepines; Cardiotonic Agents; Disease Models, Animal; Heart Rate; Humans; Ivabradine; Myocardial Infarction; Myocardial Reperfusion Injury; Ventricular Remodeling | 2008 |
Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice.
Topics: Animals; Anti-Arrhythmia Agents; Aorta; Apolipoproteins E; Atherosclerosis; Benzazepines; Blood Pressure; Cholesterol, Dietary; Collagen; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Fibrosis; Heart Rate; Impotence, Vasculogenic; Ivabradine; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Oxidative Stress; Penile Erection; Penis; Superoxides; Time Factors; Vasodilation; Vasodilator Agents | 2010 |
Ivabradine reduces chemokine-induced CD4-positive lymphocyte migration.
Topics: Actins; Animals; Antigens, CD; Atherosclerosis; Benzazepines; CD4-Positive T-Lymphocytes; Cell Adhesion Molecules; Cell Movement; Chemokine CCL5; Chemokine CXCL12; Chemokines; Enzyme Activation; Enzyme Inhibitors; Humans; Ivabradine; Mice; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; rac1 GTP-Binding Protein | 2010 |
Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis.
Topics: Animals; Anti-Arrhythmia Agents; Apolipoproteins E; Arteries; Atherosclerosis; Benzazepines; Capillaries; Collateral Circulation; Cyclic Nucleotide-Gated Cation Channels; Cytokines; Heart Rate; Hypercholesterolemia; Ivabradine; Ligation; Mice; Nitric Oxide Synthase Type III; Reactive Oxygen Species; Stress, Physiological | 2012 |
Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice.
Topics: Animals; Anti-Arrhythmia Agents; Apolipoproteins B; Atherosclerosis; Benzazepines; Carotid Arteries; Carotid Artery Diseases; Cerebral Arteries; Cerebrovascular Disorders; Compliance; Disease Models, Animal; Disease Progression; Dyslipidemias; Endothelium, Vascular; Exercise Therapy; Genotype; Heart Rate; Humans; Ivabradine; Male; Matrix Metalloproteinase 9; Metoprolol; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Nitric Oxide; Nitric Oxide Synthase Type III; Phenotype; Receptors, LDL; Severity of Illness Index; Stress, Mechanical; Time Factors; Vasodilation | 2011 |
Differential effects of heart rate reduction with ivabradine in two models of endothelial dysfunction and oxidative stress.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Benzazepines; Chromatography, High Pressure Liquid; Disease Models, Animal; Endothelium, Vascular; Heart Rate; Hemodynamics; Humans; Hypertension; Immunoblotting; Ivabradine; Luminescence; Male; Mice; Mice, Knockout; Neutrophils; Oxidative Stress; Rats; Rats, Wistar; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Benzazepines; Cells, Cultured; Cholesterol, Dietary; Endothelium, Vascular; Heart Rate; Ivabradine; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Oxidative Stress; Tachycardia | 2008 |